Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Postoperative intensity-modulated arc therapy for cervical and endometrial cancer: a prospective report on toxicity.
Vandecasteele K, Tummers P, Makar A, van Eijkeren M, Delrue L, Denys H, Lambert B, Beerens AS, Van den Broecke R, Lambein K, Fonteyne V, De Meerleer G. Vandecasteele K, et al. Among authors: fonteyne v. Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):408-14. doi: 10.1016/j.ijrobp.2011.12.020. Epub 2012 Feb 28. Int J Radiat Oncol Biol Phys. 2012. PMID: 22377596
The current use of the EORTC QLQ-NMIBC24 and QLQ-BLM30 questionnaires for the assessment of health-related quality of life in bladder cancer patients: a systematic review.
Rammant E, Fox L, Beyer K, Aaronson NK, Chaloner R, De Padova S, Liedberg F, Wintner LM, Decaestecker K, Fonteyne V, Perdek N, Wylie H, Catto JWF, Ripping TM, Holzner B, Van Leeuwen M, Van Hemelrijck M; EORTC Quality of Life Group. Rammant E, et al. Among authors: fonteyne v. Qual Life Res. 2023 Aug;32(8):2127-2135. doi: 10.1007/s11136-022-03335-4. Epub 2023 Jan 17. Qual Life Res. 2023. PMID: 36648569 Review.
Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity.
Fonteyne V, De Neve W, Villeirs G, De Wagter C, De Meerleer G. Fonteyne V, et al. Radiother Oncol. 2007 Aug;84(2):156-63. doi: 10.1016/j.radonc.2007.06.013. Epub 2007 Aug 10. Radiother Oncol. 2007. PMID: 17692976
Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.
Arcangeli S, Strigari L, Soete G, De Meerleer G, Gomellini S, Fonteyne V, Storme G, Arcangeli G. Arcangeli S, et al. Among authors: fonteyne v. Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):39-45. doi: 10.1016/j.ijrobp.2008.04.005. Epub 2008 Jun 4. Int J Radiat Oncol Biol Phys. 2009. PMID: 18538488 Clinical Trial.
Volumetric modulated arc therapy for delivery of prostate radiotherapy: in regard to Palma et al. (Int J Radiat Oncol Biol Phys 2008;70:996-1001).
Ost P, Fonteyne V, De Neve W, De Gersem W, De Wagter C, Vandecasteele K, Duprez F, De Meerleer G. Ost P, et al. Among authors: fonteyne v. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1286; author reply 1287. doi: 10.1016/j.ijrobp.2008.12.008. Int J Radiat Oncol Biol Phys. 2009. PMID: 19251105 No abstract available.
152 results